Abstract: The present invention provides a novel method for determining cancer malignancy, a novel cancer diagnostic method, a novel method for determining prognosis, a novel vaccine for cancer treatment, and a novel vaccine for suppressing cancer metastasis. Specifically, the invention provides a cancer malignancy evaluation method that comprises the step of measuring a DDX3X expression level in a cancer tissue, and the step of evaluating malignancy of the cancer tissue by using the DDX3X expression level.

Abstract: The present invention aims at solving the problems of conventional methods for producing an 18F-labeled compound, that is, the problem of purification of a compound in a liquid phase synthesis method and the problem of an insufficient yield due to the reduction of reactivity in a solid phase synthesis method. There is provided a method for producing an 18F-labeled compound including: allowing a high molecular compound containing a residue of a precursor compound to be labeled and a residue of a phase transfer catalyst in the molecule thereof to react with 18F?; and removing the 18F-labeled compound from the high molecular compound.

Abstract: Silica particles having 4-30% of an organopolysiloxane grafted to surfaces thereof are provided. A silicone composition loaded with such silica particles has high transparency, minimized permeability to corrosive gases, and improved encapsulation ability.

Abstract: The purpose of the present invention is to provide a better intestine immunomodulator. The intestine immunomodulator of the present invention comprises bacterial cells or a bacterial component of a Lactobacillus paracasei K71 strain having an international deposit No.: FERM BP-11098 as an active ingredient. Preferably, the intestine immunomodulator is used to facilitate production of secretory immunoglobulin A or to activate natural killer cells.

Abstract: Provided is a process for production of composite fine particles with heterogeneous surfaces. The process ensures a high productivity and enables a voluntary control of particle diameters. Further, the process imposes no restrictions on heterogeneous substances added for functional expression, and allows a heterogeneous substance to be encapsulated in central portions of composite fine particle spheres. A composite film obtained by laminating two or more kinds of films is cut into minute pieces, followed by melting the same to obtain spherical minute pieces. Particularly, liquid films are separately formed with two or more kinds of liquids containing polymerizable monomers. Further, two or more kinds of films can thereby be obtained through polymerization. The two or more kinds of films thus obtained are then laminated to further allow polymerization to take place, thus obtaining the composite film.

Abstract: A device for recovering heat of molten slag, having a simple structure and high heat recovery efficiency. The device includes: a fluidized bed (3) formed of a fluidized bed material (32) composed of a crushed solidified slag; a slag pool (4) for feeding a molten slag to the fluidized bed; heat transfer tubes (7) for recovering heat from the fluidized bed; and a solidified slag withdrawing device (21) for recovering a solidified slag (34), such solidified slag (34) being formed in the fluidized bed as the molten slag is solidified therein. Molten slag droplets (31) are dripped into the fluidized bed (3) from the slag pool (4) and solidified in the corresponding fluidized bed. The heat released at that time is transferred to the heat transfer tubes (7) through the bed material (32).

Abstract: There are provide a silicate-based phosphor excellent in emission intensity and a manufacturing method of the same. A manufacturing method of a silicate-based phosphor is characterized by: introducing in a vessel raw material powders having a compound containing light-emitting ions selected from at least one of Eu, Ce, Mn, and Tb; and firing the raw material powders while supplying SiOx (0.5?x?1.9, preferably, 0.8?x?1.2) in a gas phase. The raw material powders preferably further contains at least one of an alkali metal compound, an alkaline-earth metal compound, a magnesium compound, and a rare-earth compound. The silicate-based phosphor is preferably M2SiO4:Eu2+ (wherein M is one or more selected from a group consisting of Ca, Sr and Ba). The firing is preferably performed by supplying the SiOx to the raw material powders in a gas atmosphere at a temperature of 1200 to 1700° C. and subjecting the raw material powders to a gas-solid phase reaction at a temperature of 700 to 1700° C.

Abstract: The present invention provides methods for retaining and expressing physiologically active substances in a target tissue-specific-manner, by administering the physiologically active substances to target submucous tissue. Specifically, the present inventors demonstrated that, when physiologically active substances were directly administered into submucous tissues without using a carrier, the physiologically active substances were effectively and safely retained at the administration sites over long periods without loss and diffusion, and produced the effect acting in a reservoir-like fashion. The physiologically active substances administered as described above were demonstrated to produce the therapeutic effect without having an influence on organs other than the administered organ.

Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.

Abstract: This invention provides a method for measuring human megalin that can be performed in a simpler manner within a shorter period of time than is possible with conventional techniques, and that can also quantify human megalin. This invention also provides a method that enables diagnosis of functional diseases, which are specific to cells, tissues, or organs, in a site-directed manner at an early stage. Measurement of human megalin enables detection of a disease in an organ in which megalin expression is observed.

Abstract: Provided are a functional-group-modified carbon material modified with an isocyanate group or amino group, and a method for producing the material. The material is an isocyanate-group-modified carbon material in which an isocyanate group of a diisocyanate compound is bonded to a graphene-like carbon material, or an amino-group-modified carbon material in which a fragment obtained by radical-decomposing an amino-group-containing azo-type radical initiator is added to the graphene-like carbon material by radical-trapping. The method is a method for producing a functional-group-modified carbon material, including heating and stirring, in a solvent, a graphene-like carbon material, and a diisocyanate compound or an amino-group-containing azo-type radical initiator.

Abstract: This invention provides a diagnostic kit and a diagnostic marker used for diagnosing a renal disease. This invention also provides a method for detecting a renal disease comprising measuring at least one type of human megalin existing in urine selected from among full-length human megalin and human megalin fragments of (i) to (iii): (i) full-length human megalin; (ii) a human megalin endodomain fragment lacking a human megalin ectodomain; and (iii) a human megalin ectodomain fragment lacking a human megalin endodomain.

Abstract: Methods and pharmaceutical compositions for treating severe ischemic events including cerebral infarction, cardiac infarction, or pulmonary embolism, comprising a thrombolytic intervention including thrombolytic agents and an inhibitor of vascular endothelial growth factor (VEGF) receptor-mediated signal transduction are disclosed.

Abstract: An object is to provide a Tol1 element transposase and a use thereof. Provided is a Tol1 element transposase containing (a) a protein having the amino acid sequence of SEQ ID No: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence of SEQ ID NO: 1 and having an enzymatic activity for transferring Tol1 element. Further, provided is a polynucleotide encoding the transposase and an expression construct containing the polynucleotide therein. The present invention also provides a DNA introduction system including (a) a donor factor having such a structure that a desired DNA is inserted in a transposase gene-defected Tol1 element and (b) a helper factor containing the transposase or the polynucleotide.

Abstract: This invention provides a simple means for detecting a renal disorder, a diagnostic marker for a renal disorder that enables prognostic prediction of a renal disorder (e.g., diabetic nephropathy and IgA nephropathy) and evaluation of the degree of nephropathy at the phase of stage-II diabetic nephropathy by measuring the megalin level in urine associated with a renal disorder used for the detection means, and use of such marker. The invention also provides the use of human megalin obtained from the urine sample of a subject as a marker for detecting a renal disorder.

Abstract: An object is to provide a Tol1 element transposase and a use thereof. Provided is a Tol1 element transposase containing (a) a protein having the amino acid sequence of SEQ ID No: 1 or (b) a protein having an amino acid sequence homologous to the amino acid sequence of SEQ ID NO: 1 and having an enzymatic activity for transferring Tol1 element. Further, provided are a polynucleotide encoding the transposase and an expression construct containing the polynucleotide therein. The present invention also provides a DNA introduction system including (a) a donor factor having such a structure that a desired DNA is inserted in a transposase gene-defected Tol1 element and (b) a helper factor containing the transposase or the polynucleotide.

Abstract: A compression device is provided which allows anyone to easily uniformly and thinly compress fibrin-gel without damage. A fibrin-gel compression device 1 includes: a first member 10 having a handle part 11 and a pressing convex part 12; and a second member 20 having a handle part 21 and an accommodating concave part 22 forming a shape corresponding to the pressing convex part. The first and second members are characterized by being partially joined or rotatably supported to each other to variably adjust a separation distance d between the pressing convex part and the accommodating concave part to be able to accommodate and compress fibrin-gel 30 therebetween. Further, it is preferable that a shape difference is provided between the convex part 12 and the concave part 22 or a stopper member is provided on at least one of the handle parts 12, 21 to provide the separation distance d of 1 mm to 2 mm when compressing the fibrin-gel 30.

Abstract: A method for producing a silicate-based oxynitride phosphor, comprising a step of firing a raw material mixture while contacting the raw material mixture with a Si-containing gas containing gas phase Si to generate a silicate-based oxynitride phosphor.

Abstract: A crystalline material represented by M12a(M2bLc)M3dOyNx wherein M1 is at least one element selected from alkali metals, M2 is at least one element selected from Ca, Sr, and Ba, M3 is at least one element selected from Si and Ge, L is at least one element selected from rare earth elements, Bi, and Mn, a is 0.9 to 1.5, b is 0.8 to 1.2, c is 0.005 to 0.2, d is 0.8 to 1.2, x is 0.001 to 1.0, and y is 3.0 to 4.0 or less.

Abstract: A method for producing a crystalline material comprising a step of firing a raw material mixture containing M1, M2, M3, and L in an atmosphere containing NH3 gas to generate a crystalline material represented by M12a(M2bLc)M3dOyNx